10q10k10q10k.net
Pyxis Oncology, Inc.

Pyxis Oncology, Inc.PYXSEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative antibody-based immuno-oncology therapies for hard-to-treat solid tumors and hematological malignancies. Its core pipeline features multiple candidates designed to activate the human immune system against cancer cells, with primary operations and target markets across North America and select European regions.

Q3 2025Q2 2025Q3 2024Q2 2024Q1 2024

PYXS Q3 FY2025 Key Financial Metrics

Revenue

$0

Gross Profit

N/A

Operating Profit

$-23.5M

Net Profit

$-22.0M

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

YoY Growth

N/A

EPS

$-0.35

Pyxis Oncology, Inc. Q3 FY2025 Financial Summary

Pyxis Oncology, Inc. reported revenue of $0 for Q3 FY2025, with a net profit of $-22.0M (down 3.8% YoY) (N/A margin).

Key Financial Metrics

Total Revenue$0
Net Profit$-22.0M
Gross MarginN/A
Operating MarginN/A
Report PeriodQ3 FY2025

Pyxis Oncology, Inc. Quarterly Revenue & Net Profit History

Pyxis Oncology, Inc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q3 FY2025$0—$-22.0MN/A
Q2 FY2025$2.8M—$-18.4M-650.9%
Q3 FY2024$0—$-21.2MN/A
Q2 FY2024$0—$-17.3MN/A
Q1 FY2024$16.1M—$-3.3M-20.2%

Income Statement

Q1 2024Q2 2024Q3 2024Q2 2025Q3 2025
Revenue$16.1M$0$0$2.8M$0
YoY GrowthN/AN/AN/AN/AN/A

Balance Sheet

Q1 2024Q2 2024Q3 2024Q2 2025Q3 2025
Assets$220.2M$208.4M$195.3M$123.2M$105.6M
Liabilities$36.1M$38.6M$41.6M$35.6M$36.8M
Equity$184.2M$169.8M$153.7M$87.6M$68.8M

Cash Flow

Q1 2024Q2 2024Q3 2024Q2 2025Q3 2025
Operating CF$-20.7M$-3.0M$-14.7M$-17.3M$-13.3M